Anästhesiol Intensivmed Notfallmed Schmerzther 2014; 49(11/12): 670-680
DOI: 10.1055/s-0040-100121
Fachwissen
Schmerzmedizin
© Georg Thieme Verlag Stuttgart · New York

Diclofenac up2date – Teil 2: Einsatz bei speziellen Patientengruppen

Diclofenac up2date – Part 2: The use in specific groups of patients
Stefan Bushuven
,
Daniel Heise
,
Juliane Bolbrinker
Further Information

Publication History

Publication Date:
09 January 2015 (online)

Zusammenfassung

Das Nicht-Opioid-Analgetikum Diclofenac wird weltweit zur Therapie muskuloskelettaler und perioperativer Schmerzen eingesetzt. Nicht zuletzt wegen der freien Verfügbarkeit niedrigdosierter Präparate als “over-the-counter“-Medikament müssen renale, gastrointestinale und kardiale unerwünschte Wirkungen berücksichtigt werden. Die Vielzahl der verfügbaren Applikationsformen (u.a. Tabletten, Zäpfchen, Tropfen, Gele, Pflaster) mit ihren jeweils spezifischen zugelassenen Indikationen, Dosierungsempfehlungen und Anwendungsbeschränkungen kann verwirrend sein und sowohl einen inadäquaten Einsatz als auch die Vorenthaltung eines potenten Analgetikums bedingen. Die vorliegende Übersichtsarbeit soll Anästhesisten, Schmerztherapeuten und Intensivmedizinern die wichtigsten Aspekte dieser weit verbreiteten Substanz für den Einsatz bei bestimmten Krankheitsbildern und Patientengruppen präsentieren.

Abstract

The non-opioid analgesic diclofenac is used worldwide for musculoskeletal and perioperative pain therapy. Despite its frequent use and easy access as an “over the counter” drug, gastrointestinal, cardiovascular, and renal adverse drug effects have to be considered. Availability of diverse formulations (e.g. tablets, suppository, gel-formulations) with different indications, dosage recommendations and contraindications may easily lead to confusion, thus accounting for inadequate use on the one hand or withholding of an effective analgesic. This review may provide physicians in perioperative medicine, intensive care and pain therapy with important and suitable information about the pharmacology and appropriate use of this drug.

Kernaussagen

  • Diclofenac sollte bei Schwangeren im 3. Trimenon und bei Säuglingen nicht verwendet werden.

  • Der Einsatz von Diclofenac bei Kindern < 14 Jahre erfolgt überwiegend „off-label“, ist aber vermutlich sicher (bei unsicherer Datenlage zur optimalen Dosis).

  • Topisches Diclofenac ist bei Patienten mit Hand- oder Kniearthrose ebenso wirksam wie systemisches, weist aber eine geringere Rate an unerwünschten Arzneimittelwirkungen auf.

Ergänzendes Material

 
  • Literatur

  • 1 Fachinformationen, R.L. Fachinformationen Diclofenac. Fachinformation. 2013
  • 2 Eustace N, O'Hare B. Use of nonsteroidal anti-inflammatory drugs in infants. A survey of members of the Association of Paediatric Anaesthetists of Great Britain and Ireland. Paediatr Anaesth 2007; 17: 464-469
  • 3 Standing JF et al. Diclofenac for acute pain in children. Cochrane Database Syst Rev CD 005538 2009;
  • 4 Burdan F, Staroslawska E, Szumilo J. Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors. Pharmacol Rep 2012; 64: 521-527
  • 5 Ofori B et al. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006; 77: 268-279
  • 6 Embryotox.Embryotox. 2013
  • 7 Nakhai-Pour HR et al. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 2011; 183: 1713-1720
  • 8 Nezvalova-Henriksen K, Spigset O, Nordeng H. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG 2013; 120: 948-959
  • 9 Mersal A, Attili I, Alkhotani A. Severe neonatal pulmonary hypertension secondary to antenatal maternal diclofenac ingestion reversed by inhaled nitric oxide and oral sildenafil. Ann Saudi Med 2007; 27: 448-449
  • 10 Siu KL, Lee WH. Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension. J Paediatr Child Health 2004; 40: 152-153
  • 11 Zenker M et al. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. J Perinat Med 1998; 26: 231-234
  • 12 Spigset O, Hagg S. Analgesics and breast-feeding: safety considerations. Paediatr Drugs 2000; 2: 223-238
  • 13 McGettigan Henry D. Use of non–steroidal anti–inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high–income countries. PLoS Med 2013; 10
  • 14 Schjerning Olsen AM et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123: 2226-2235
  • 15 Wise J. Diclofenac shouldn't be prescribed to people with heart problems, drug agency says. BMJ 2013; 347
  • 16 Krotz F, Struthmann L.A. Review on the risk of myocardial infarction associated with the NSAID diclofenac. Cardiovasc Hematol Disord Drug Targets 2010; 10: 53-65
  • 17 Reddy KS, Roy A. Cardiovascular risk of NSAIDs: time to translate knowledge into practice. PLoS Med 2013; 10
  • 18 Krum H et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther 2012; 30: 342-50
  • 19 Collaboration NT et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769-779
  • 20 Agency EM. New safety advice for diclofenac – CMDh endorses PRAC recommendation. Online webpage 2013;
  • 21 Olsen AM, Gislason GH, Fosbol EL. Time-perspective in cardiovascular risk of NSAID use after first-time myocardial infarction. Curr Opin Cardiol 2013; 28: 683-688
  • 22 Brenner SS et al. Influence of age and cytochrome P450 2C9 genotype on the steady–state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42: 283-292
  • 23 Barkin RL et al. Should nonsteroidal anti–inflammatory drugs (NSAIDs) be prescribed to the older adult?. Drugs Aging 2010; 27: 775-789
  • 24 Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin 2011; 27: 1359-1366
  • 25 Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099
  • 26 Juhlin T, Bjorkman S, Hoglund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE–inhibitors. Eur J Heart Fail 2005; 7: 1049-1056
  • 27 Gooch K et al. NSAID use and progression of chronic kidney disease. Am J Med 2007; 120: 1-7
  • 28 O'Neil CK, Hanlon JT, Marcum ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 2012; 10: 331-342
  • 29 White WB. Defining the problem of treating the patient with hypertension and arthritis pain. Am J Med 2009; 122 (Suppl. 01) 3-9
  • 30 American Geriatrics Society Beers Criteria Update Expert. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60: 616-631
  • 31 Holt S, Schmiedl S, Thurmann A. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 2010; 107: 543-551
  • 32 Dräger D, Budnick A, Kreutz R, Kopf A. Schmerz im Alter. Monographie 2014; 1-1
  • 33 Roth SH, Fuller P. Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older. Clin Interv Aging 2012; 7: 127-137
  • 34 Baraf HS et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging 2011; 28: 27-40
  • 35 Peniston JH et al. Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Clin Interv Aging 2012; 7: 517-523
  • 36 Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev CD 007400 2012; 9
  • 37 Stierlin H, Faigle JW, Colombi A. Pharmacokinetics of diclofenac sodium (Voltaren) and metabolites in patients with impaired renal function. Scand J Rheumatol Suppl 1978; 30-35
  • 38 Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney. J Assoc Physicians India 2004; 52: 632-640
  • 39 Ruilope LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?. Acta Diabetol 2005; 42 (Suppl. 01) 33-41
  • 40 Juhlin T et al. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail 2004; 6: 909-916
  • 41 Nygard P et al. Effects of short-term addition of NSAID to diuretics and/or RAAS-inhibitors on blood pressure and renal function. Int J Clin Pharm 34: 468-474
  • 42 Farker K et al. Effects of short-term treatment with diclofenac-colestyramine on renal function and urinary prostanoid excretion in patients with type-2 diabetes. Eur J Clin Pharmacol 2002; 58: 85-91
  • 43 Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184-213
  • 44 Zimmerer J, Tittor W, Degen P. [Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease]. Fortschr Med 1982; 100: 1683-1688
  • 45 Lill JS et al. Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. J Clin Pharmacol 2000; 40: 250-257
  • 46 Laine L et al. How common is diclofenac–associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009; 104: 356-362
  • 47 Aithal G. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin Drug Saf 2004; 3: 519-523
  • 48 Aithal G et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430-1440
  • 49 Raineri-Gerber I, von Felten A. [Inhibition of thrombocyte function by non–steroidal anti–rheumatic agents: a comparative study between diclofenac, acemetacin, mefenamic acid and ibuprofen]. Schweiz Med Wochenschr 1991; 121: 783-787
  • 50 Schmidt A, Bjorkman S, Akeson J. Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss. Acta Anaesthesiol Scand 2001; 45: 48-52
  • 51 Cormio M, Citerio G. Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care. Neurocrit Care 2007; 6: 82-89
  • 52 Surakarn J, Tannirandorn Y. Intramuscular diclofenac for analgesia after cesarean delivery: a randomized controlled trial. J Med Assoc Thai 2009; 92: 733-737
  • 53 Dahl V et al. High-dose diclofenac for postoperative analgesia after elective caesarean section in regional anaesthesia. Int J Obstet Anesth 2002; 11: 91-94
  • 54 Aronoff DM. Cyclooxygenase inhibition in sepsis: is there life after death?. Mediators Inflamm 2012; 2012: 696897-696897
  • 55 Sciuto AM, Stotts RR, Hurt HH. Efficacy of ibuprofen and pentoxifylline in the treatment of phosgene–induced acute lung injury. J Appl Toxicol 1996; 16: 381-384
  • 56 Tramer MR et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85: 169-182
  • 57 Castellsague J et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127-1146
  • 58 Abraham NS et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010; 105: 2533-2549
  • 59 Aftab AR et al. NSAID-induced colopathy. A case series. J Gastrointestin Liver Dis 2010; 19: 89-91
  • 60 Stolte M, Hartmann FO. Misinterpretation of NSAID-induced Colopathy as Crohn's disease. Z Gastroenterol 2010; 48: 472-475
  • 61 Takeuchi K et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202
  • 62 Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003; 217: 89-98
  • 63 Jose J et al. Drug use in porphyria: a therapeutic dilemma. Singapore Med J 2008; 49: 272-275
  • 64 DGAI. Empfehlung zur Durchführung von Anästehsien bei Patienten mit Porphyrie. DGAInfo 2008;
  • 65 Diclofenac. Online webpage 2013; Drugs.com.
  • 66 eHealthMe.Review: Acute intermittend porphyria in Diclofenac. Webpage. 2013
  • 67 Minder E. Merkblatt Arzneimittel bei akuten Porphyrien. Webpage 2009
  • 68 Ulrich C et al. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010; 20: 482-488
  • 69 Jacobi J et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30: 119-141
  • 70 Farnam K et al. Nonallergic drug hypersensitivity reactions. Int Arch Allergy Immunol 2012; 159: 327-345
  • 71 Kowalski ML et al. Hypersensitivity to nonsteroidal anti–inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66: 818-829
  • 72 Harrer A et al. Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PLoS One 2010; 5
  • 73 van Puijenbroek E et al. Different risks for NSAID-induced anaphylaxis. Ann Pharmacother 2002; 36: 24-29
  • 74 van der Klauw MM, Wilson JH, Stricker BH. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974–1994) and review of the literature. Clin Exp Allergy 1996; 26: 1355-1363
  • 75 Leone R et al. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database. Drug Saf 2005; 28: 547-556
  • 76 Riemer AB et al. Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model. Clin Exp Allergy 2010; 40: 486-493
  • 77 Lynde CB, Pierscianowski TA, Pratt MD. Allergic contact dermatitis caused by diclofenac cream. CMAJ 2009; 181: 925-926
  • 78 Miyazato H et al. Allergic contact dermatitis due to diclofenac sodium in eye drops. J Dermatol 2011; 38: 276-279
  • 79 Fernandez-Jorge B et al. Photoallergic contact dermatitis due to diclofenac with cross–reaction to aceclofenac: two case reports. Contact Dermatitis 2009; 61: 236-237
  • 80 Kleyn CE, Bharati A, King CM. Contact dermatitis from 3 different allergens in Solaraze gel. Contact Dermatitis 2004; 51: 215-216
  • 81 Jonker MJ, Bruynzeel D. Anaphylactic reaction elicited by patch testing with diclofenac. Contact Dermatitis 2003; 49: 114-115
  • 82 Gomez A et al. Allergic contact dermatitis due to indomethacin and diclofenac. Contact Dermatitis 2000; 43: 59-59
  • 83 Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev CD 008783 2013; 4
  • 84 Dubey R, Martini LG, Christie M. Duel-Acting Subcutaneous Microemulsion Formulation for Improved Migraine Treatment with Zolmitriptan and Diclofenac: Formulation and In Vitro-In Vivo Characterization. AAPS J 2013; 16: 214-220
  • 85 Haag G et al. Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migrane und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft fur Neurologie (DGN), the Osterreichische Kopfschmerzgesellschaft (OKSG) and the Schweizerische Kopfwehgesellschaft (SKG). J Headache Pain 2011; 12: 201-217
  • 86 May A et al. [Treatment and prophylaxis for cluster headaches and other trigeminal autonomic headaches. Revised recommendations of the German Migraine and Headache Society]. Schmerz 2005; 19: 225-241
  • 87 Fang J et al. Pharmacological interventions for phantom limb pain. Chin Med J (Engl) 2013; 126: 542-549
  • 88 JT.Phantom Limb Pain: Current and Emerging Treatments.US Pharmacist Webpage. 2013
  • 89 AWMF.S1-Leitlinie: Pharmakologische Therapie chronisch neuropathsicher Schmerzen. 2012
  • 90 Jage J. [Perioperative analgesia in adults : The concept of balanced analgesia.]. Schmerz 1993; 7: 140-153
  • 91 Gogarten W, Van Aken H., Buettner J, Riess H, Wulf H, Buerkle H. Regional anaesthesia and thromboembolism prophylaxis/anticoagulation –Revised recommendations of the German Society of Anaesthesiology and IntensiveCare Medicine. Anästh Intensivmed 2007; 48: 109-124
  • 92 Agarwal A et al. Transdermal diclofenac patch vs eutectic mixture of local anesthetics for venous cannulation pain. Can J Anaesth 2007; 54: 196-200
  • 93 Forget P et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 2013; 20 (Suppl. 03) 650-660
  • 94 Forget P et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth 2014; 113 (Suppl. 01)
  • 95 Klein M. Postoperative non-steroidal anti-inflammatory drugs and colorectal anastomotic leakage. NSAIDs and anastomotic leakage. Dan Med J 2012; 59
  • 96 Valle BL et al. Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One 2013; 8
  • 97 Bahner JD, Bordeaux JS. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol 2013; 31: 792-798
  • 98 Kim JH et al. Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Int J Cancer 2008; 122: 1765-1773
  • 99 Kim KS et al. Cyclooxygenase inhibitors induce apoptosis in oral cavity cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Biochem Biophys Res Commun 2004; 325: 1298-1303
  • 100 Perttunen K, Nilsson E, Kalso E. I.v. diclofenac and ketorolac for pain after thoracoscopic surgery. Br J Anaesth 1999; 82: 221-227
  • 101 Perttunen K et al. IV diclofenac in post-thoracotomy pain. Br J Anaesth 1992; 68: 474-480
  • 102 Biyik I et al. Efficacy of gabapentin versus diclofenac in the treatment of chest pain and paresthesia in patients with sternotomy. Anadolu Kardiyol Derg 2009; 9: 390-396
  • 103 Opitz I et al. Perioperative diclofenac application during video-assisted thoracic surgery pleurodesis modulates early inflammatory and fibrinolytic processes in an experimental model. Eur Surg Res 2013; 50: 14-23
  • 104 Ors Kaya S et al. Effect of diclofenac on experimental pleurodesis induced by tetracycline in rabbits. J Investig Med 2005; 53: 267-270
  • 105 Teixeira LR et al. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc. Chest 2005; 128: 4041-4045
  • 106 Lardinois D et al. Non-steroidal anti-inflammatory drugs decrease the quality of pleurodesis after mechanical pleural abrasion. Eur J Cardiothorac Surg 2004; 25: 865-871
  • 107 Ben-Nun A et al. Nonsteroidal antiinflammatory medications: efficient and safe treatment following video–assisted pleurodesis for spontaneous pneumothorax. World J Surg 2011; 35: 2563-2567
  • 108 Hunt I et al. Using non-steroidal anti-inflammatory drugs (NSAIDs) following pleurodesis. Interact Cardiovasc Thorac Surg 2007; 6: 102-104
  • 109 Schiefecker AJ et al. Parenteral diclofenac infusion significantly decreases brain-tissue oxygen tension in patients with poor-grade aneurysmal subarachnoid hemorrhage. Crit Care 2013; 17
  • 110 Lumawig JM, Yamazaki A, Watanabe K. Dose-dependent inhibition of diclofenac sodium on posterior lumbar interbody fusion rates. Spine J 2009; 9: 343-349
  • 111 Filippi R et al. Postoperative pain therapy after lumbar disc surgery. Acta Neurochir 1999; 141: 613-618
  • 112 Izquierdo E et al. [Postoperative analgesia in herniated disk surgery. Comparative study of diclofenac , lysine acetylsalicylate, and ketorolac]. Rev Esp Anestesiol Reanim 1995; 42: 316-319
  • 113 Yukawa Y et al. A prospective randomized study of preemptive analgesia for postoperative pain in the patients undergoing posterior lumbar interbody fusion: continuous subcutaneous morphine, continuous epidural morphine, and diclofenac sodium. Spine 2005; 30: 2357-2361